Estimating recurrences prevented and costs avoided with atezolizumab in early non-small cell lung cancer in the United States.

ABSTRACT:

Background

Recurrence of early-stage non-small cell lung cancer (eNSCLC) is associated with significant mortality and costs. Atezolizumab (ATZ) was recently approved as adjuvant treatment following resection and platinum-based chemotherapy for adults with stage II-IIIA NSCLC with PD-L1 expression ≥1% after demonstrating significant improvement in disease-free survival (DFS) relative to best supportive care (BSC) in the IMpower010 trial (NCT02486718). This study evaluated the population-level impact of ATZ as adjuvant treatment for eNSCLC in the United States by estimating the number and costs of recurrences avoided.

Methods

A Monte Carlo simulation model estimated the cumulative number of recurrences and deaths prevented, along with direct, indirect, and terminal care costs,

SUBMITTER: Sharma R 

PROVIDER: S-EPMC10067035 | biostudies-literature | 2023 Mar

REPOSITORIES: biostudies-literature